Intervention in COVID-19 linked hypercoaguable states characterized by circuit thrombosis utilizing a direct thrombin inhibitor.

利用直接凝血酶抑制剂干预以回路血栓形成为特征的 COVID - 19 相关高凝状态。

• 发表时间: 2020 Dec
• 来源期刊: Thromb Update
• DOI: 10.1016/j.tru.2020.100009
• PMID: 38620488
• 文章类型: Journal Article
• 作者列表: Seshadri M,Ahamed J,Laurence J

关键词: Direct thrombin inhibitor; Fibrinogen; Thrombotic complications

Abstract

•Circuit thrombosis complicates CRRT in COVID-19 despite standard heparin-based anticoagulation regimens.•5 cases of CRRT thrombosis despite heparin-based anticoagulation resolved using a direct thrombin inhibitor, argatroban.•Changes in fibrinogen levels better reflected response to anticoagulation than did changes in D-dimer levels.•High fibrinogen levels and decreased anti-thrombin III activity may relate to argatroban superiority in these cases.

摘要

•尽管有标准的肝素抗凝方案，但COVID-19的回路血栓形成会使CRRT复杂化。•5例CRRT血栓形成，尽管使用直接凝血酶抑制剂以肝素为基础的抗凝治疗，阿加曲班。•纤维蛋白原水平的变化比D-二聚体水平的变化更好地反映抗凝反应。•在这些情况下，高纤维蛋白原水平和抗凝血酶III活性降低可能与阿加曲班优势有关。